` INO (Inovio Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

INO
vs
S&P 500

Over the past 12 months, INO has underperformed S&P 500, delivering a return of -76% compared to the S&P 500's 9% growth.

Stocks Performance
INO vs S&P 500

Loading
INO
S&P 500
Add Stock

Performance Gap
INO vs S&P 500

Loading
INO
S&P 500
Difference
www.alphaspread.com

Performance By Year
INO vs S&P 500

Loading
INO
S&P 500
Add Stock

Competitors Performance
Inovio Pharmaceuticals Inc vs Peers

S&P 500
INO
ABBV
AMGN
GILD
VRTX
Add Stock

Inovio Pharmaceuticals Inc
Glance View

Market Cap
70m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
Not Available
Back to Top